Abstract

Introduction: The modified Rankin scale (mRS) is a reliable objective measure of disability and is widely applied in clinical trials. Health-related quality of life (QOL) measurements using Neuro-QOL provide validated measures of patient-reported outcomes. We compared changes in physical function QOL scores with transitions in mRS scores after ischemic stroke or transient ischemic attack (TIA). Methods: From a single-center prospective cohort study, we identified ischemic stroke and TIA patients admitted between August 2012 and April 2013 who survived to 3-month follow-up and underwent mRS and Neuro-QOL outcomes assessments at 1 and 3 months. The mRS was assessed by structured telephone interviews and Neuro-QOL scores using short forms of upper extremity (UE) and lower extremity (LE) function. We used Pearson's coefficient to compare mRS and Neuro-QOL scores and assessed mean changes in Neuro-QOL T-scores across mRS strata and between 1 and 3 months. Results: Three-hundred twelve patients met study criteria (mean age 65.2 years; initial NIHSS score 4; 77.2% ischemic stroke). Strong correlations were noted between mRS and physical function QOL scores at 3-months: mRS-LE: r = -0.74; mRS-UE: r = -0.74. UE and LE QOL scores were 6.1 and 7.1 points lower, respectively, in those with mRS of 1 compared with 0. Within individual patients, a 1 point decrease (improvement) in mRS was associated with increase in UE and LE QOL by 5.6 and 3.3 points while a 1 point increase (worsening) in mRS was associated with a decrease in UE and LE QOL by 4.0 and 7.5 points, respectively. By mRS, 7.5% of patients had worsening by at least 1 point between 1 and 3 months while the proportion with at least 1 standard deviation (10 points) decrease in UE or LE QOL scores was 12.1% and 14.4%, respectively. Conclusions: The mRS correlates well with patient-reported scores of physical function using Neuro-QOL. However, Neuro-QOL offers a complementary tool for assessment of neurological function and may help identify finer grades of functional change over time. Using a continuous measurement of function from the patient perspective may also be more valuable to patients and improve statistical power in clinical trials.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call